Sipuleucel-T for the treatment of advanced prostate cancer - Abstract

Sipuleucel-T is an autologous cellular immunotherapy designed to stimulate an immune response to prostate cancer that prolongs the overall survival of men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (CRPC).

The clinical development program and key efficacy, safety, and immune response findings from the phase III studies are presented. The integration of sipuleucel-T into the treatment paradigm of advanced prostate cancer and future directions for research are discussed.

Written by:
Frohlich MW. Are you the author?
Executive Vice President, Research & Development and Chief Medical Officer, Dendreon Corp, Seattle, WA.

Reference: Semin Oncol. 2012 Jun;39(3):245-52.
doi: 10.1053/j.seminoncol.2012.02.004

PubMed Abstract
PMID: 22595047 Prostate Cancer Section